PPARγ Activator and Smad3 Inhibitor Combination for UCP-1 Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective solutions for promoting UCP-1 expression and converting white adipose to brown adipose to address obesity and metabolic syndrome, particularly in enhancing energy consumption and inhibiting fat accumulation.
Innovation Solution
A combination of PPARγ activators, Smad3 inhibitors, and β3 adrenaline receptor or TGR5 activators is used to promote UCP-1 expression and induce the conversion of white adipose to brown adipose, enhancing energy consumption and inhibiting fat accumulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If PPARγ activators are used alone, then UCP-1 expression is promoted, but the conversion to brown adipose is insufficient
Solution Approach 1:
The patent combines PPARγ activators with Smad3 inhibitors and/or β3 adrenaline receptor or TGR5 activators to create a synergistic effect that promotes both UCP-1 expression and conversion to brown adipose, resolving the insufficiency of using PPARγ activators alone
Solution Approach 2:
The invention uses composite pharmaceutical compositions containing multiple active ingredients (PPARγ activator + Smad3 inhibitor and/or β3 adrenaline receptor or TGR5 activator) that work together to achieve both increased UCP-1 expression and effective brown adipose conversion
2Use of energy by moving object
If Smad3 inhibitors are used alone, then energy consumption is promoted, but UCP-1 expression is insufficient
Solution Approach 1:
The patent merges Smad3 inhibitors with PPARγ activators and/or β3 adrenaline receptor or TGR5 activators to achieve both increased energy consumption through UCP-1 activation and sufficient UCP-1 expression levels
3Temperature
If β3 adrenaline receptor activators are used alone, then heat production is promoted, but fat accumulation inhibition is insufficient
Solution Approach 1:
The invention combines β3 adrenaline receptor activators with PPARγ activators and/or Smad3 inhibitors to enhance both heat production and fat accumulation inhibition through coordinated upregulation of UCP-1 and activation of brown adipose tissue
Solution Approach 2:
The composite pharmaceutical composition integrates multiple mechanisms (PPARγ activation, Smad3 inhibition, and/or β3 adrenaline receptor or TGR5 activation) to simultaneously achieve heat production and fat accumulation inhibition
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination significantly increases UCP-1 expression, leading to increased energy consumption, improved lipid and carbohydrate metabolism, and reduced fat accumulation, effectively addressing obesity and metabolic syndrome.
Implementation Method 1
PPARγ (peroxisome proliferator-activated receptor γ), one kind of peroxisome proliferator-activated receptors, is known to prevent or ameliorate diabetes mellitus or insulin resistance through its activation
Implementation Method 2
the Smad family is an intracellular signaling factor which is phosphorylated by stimulation of a TGF-β (transforming growth factor-β) family molecule to transduce the signals thereof to the nucleus
Implementation Method 3
UCP has the function of uncoupling oxidative phosphorylation reaction in the mitochondrial inner membrane and dissipating energy as heat
Data Source
AI summary
It is intended to provide a drug, a quasi-drug, a dermatological preparation for external use, or a material to be contained to drugs, quasi-drugs, dermatological preparations for external use, food products, or the like which has an excellent UCP-1 expression-promoting action and promotes conversion of adipose to brown adipose (browning). The present invention provides a UCP-1 expression promoter comprising a PPARγ activator and a Smad3 inhibitor in combination. The present invention also provides a UCP-1 expression promoter comprising a PPARγ activator, a Smad3 inhibitor, and a β3 adrenaline receptor activator or a TGR5 activator in combination.